

Molecular Complexes of Agomelatine-Phosphoric Acid:

Crystal Structure Determination and Phase Transformation Kinetics by Non-Ambient Powder XRD

> Raja Sekhar Voguri; Praveen Chappa; Rama Reddy Chirla; <u>Archan Dey</u>

PPXRD-13 Bad Herrenalb (Germany) 18-21 May 2015

This document was presented at PPXRD -Pharmaceutical Powder X-ray Diffraction Symposium

Sponsored by The International Centre for Diffraction Data

This presentation is provided by the International Centre for Diffraction Data in cooperation with the authors and presenters of the PPXRD symposia for the express purpose of educating the scientific community.

All copyrights for the presentation are retained by the original authors.

The ICDD has received permission from the authors to post this material on our website and make the material available for viewing. Usage is restricted for the purposes of education and scientific research.



PPXRD Website – <u>www.icdd.com/ppxrd</u>

ICDD Website - www.icdd.com

Background of Development



Acetic acid Solvate (P2₁/c, Z'=1 Mp: 76° C) Form III (Pna2₁, Z'=1 Mp: 100.4° C) Form I (Pca2₁, Z'=2

Mp: 99.1° C) Form II (P2₁/c, Z'=2 Mp: 109.3° C) ✓ Novel antidepressant developed by Servier Laboratories


Dr.Reddy's


- ✓ Thermodynamically stable form-II
- ✓ Up to now, six polymorphs and several other solvates/ co-crystal (Acetic acid, Ethylene glycol, Urea, Citric Acid, Oxalic acid etc) are known
- ✓ Biopharmaceutics Classification System (BCS) class: II
- ✓ Form-I suffers from industrial process feasibility aspect
- Co-former screening, Phosphoric acid selected:
 - -- Biopharmaceutical acceptable excipient
 - -- Processeability
 - -- Stability

References: EP 2743 255 A1; Cryst. Growth & Des: 2011, **11**, 466; Cryst. Growth & Des: 2012, **12**, 2226; and AJPS: 2013, **8**, 181

Problem Statement: Solid-State Impurity








✓ Indexing is possible with (1:1) AGL:H₃PO₄ molecular complex.
✓ Extra peaks from-II is coincident, missing of main characteristic peaks like 18.6° 20.
✓ Possibility of new crystalline phase.

Thermal Studies: *DSC,TGA and Hot stage*




Microscopy



✓ Solid-solid phase transition (≈42° C), supported by hot stage microscopy; no change in morphology.
✓ AGL-P mp (118.0°) C is higher than AGL form-II (109.3° C).


Variable Temperature PXRD Studies



Dr.Reddy's

 ✓ Solid-solid phase transition leads to new polymorph (HT-Form). They are enantiotropic in nature; crystallization of RT-form happens at ≈22° C.


Kinetic Studies by DSC: Non-isothermal V DR.REDDY'S



Madal	RT -Form \rightarrow HT-Form		HT -Form \rightarrow RT-Form	m
Model	Activation Energy (KJ/Mole)	Average	Activation Energy (KJ/Mole)	Average
Kissnger	-41.0		-36.2	
Augies	-43.6	-43.6	-33.8	-33.8
FWO	-46.2		-31.4	

CETETETETES. Pharm Dev Technol, 20 OOI: 10.3109/10837450.2014.982824


Crystal Determination From Powder X-Ray Diffraction



Dr.Reddy's


Data Collection Strategies





Antor-paar Non-Ambient stage data were not suitable for Structure Determination, due to extensive preferred orientation.
Data collection for meta-stable HT-Form in transmission mode is challenging. RT-Form is converted to HT-Form externally and data is collected in foil-transmission mode. Still, few peaks of RT-Form observed; excluded for structure determination.

Crystal Structure of RT-Form




✓ Good fitting of final Rietveld refinement plot.

- ✓ (1:1) AGL-P molecular complex.
- Crystal packing: segregation of aromatic part and hydrophlic phosphoric part.
- ✓ AGL and PA forming 1-D chain running along c axis.




Crystallographic Data

Empirical Formula	$C_{15}H_{17}NO_2.H_3PO_4$
Crystal System	Monoclinic
Space Group	P2 ₁ / <i>c</i>
a (Å)	21.724(4)
b (Å)	4.599(1)
c (Å)	17.173(3)
β (°)	112.368(1)
V (Å ³)	1584.65
Ζ, Ζ΄	4, 1
$Dc (g/cm^3)$	1.431



Crystal Structure of HT-Form




- ✓ Good fitting of final Rietveld refinement plot.
- ✓ (1:1) AGL-P molecular complex.
- Crystal packing: segregation of aromatic part and hydrophlic phosphoric part.
- PA forming a dimer that connected with AGLand forming 1-D chain, running along c axis.




Crystallographic Data

Empirical Formula	$C_{15}H_{17}NO_2.H_3PO_4$
Crystal System	Monoclinic
Space Group	P2 ₁ / <i>c</i>
a (Å)	22.413(1)
b (Å)	4.598(2)
c (Å)	17.797(9)
β (°)	111.468(2)
V (Å ³)	1706.99
Ζ, Ζ΄	4, 1
$Dc (g/cm^3)$	1.328



Crystal Structure Analysis





Summary and Conclusions



✓ Crystal Structure Determination confirms

-- Both the molecular complexes of (1:1) molecular complexes of AGL-P are **co-crystal**, showing enantiotropic **polymorphism**.

✓ Correlation between kinetics and molecular level structural understanding reveals

- -- **Conformational switching** is the triggering factor of solid-solid phase transformation.
- -- At ambient temperature half life of **RT-form is more than HT-form**.
- ✓ The proposed protocol of model selection with help of Polymorph prediction could simplify the co-crystal structure determination from PXRD data.
- ✓ AGL-P co-crystal is a "pharmaceutical co-crystal" and the best alternative of AGL Form-II is terms of enhance processability as well as stability with comparable solubility.

Acknowledgement



API Project Team (Process Understanding)

- D Vamshi Krishna (Project Manager)
- Vujjini Satish Kumar (Scientist)
- Katkam Srinivas (Delivery Manager)

IPM (Discussion)

- Ch Ramesh (Director)
- A Ashok (Scientist)

Formulation Project Team (Solubility Data)

- Jigar A vyas (Scientist)
- Jaypal Reddy (Analytical Scientist)

Advanced Analytical Technology Team (Discussion and Support)

- Maheswararao Karanam (Analytical Scientist)
- Ioorika Lamare (Analytical Scientist)
- Amjad Basha Mohammad (Principal Scientist)
- V Ranga Reddy (Principal Scientist)
- Srinivasan Duraiswamy (Director)
- K Vyas (Ex-Vice President)



Thanks....